The Raf kinase inhibitor PLX5568 slows cyst proliferation in rat polycystic kidney disease but promotes renal and hepatic fibrosis.
about
Experimental therapies and ongoing clinical trials to slow down progression of ADPKDGenetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease.Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.2-Hydroxyestradiol slows progression of experimental polycystic kidney diseaseP2Y2R is a direct target of HIF-1α and mediates secretion-dependent cyst growth of renal cyst-forming epithelial cells.Hypoxia-inducible factor-1α causes renal cyst expansion through calcium-activated chloride secretion.New treatments for autosomal dominant polycystic kidney diseaseStrategies targeting cAMP signaling in the treatment of polycystic kidney disease.Tissue-engineered kidney disease models.Glucose promotes secretion-dependent renal cyst growth.Recent Trends in ADPKD Research.Validation of Effective Therapeutic Targets for ADPKD Using Animal Models.Pathways, perspectives and pursuits in polycystic kidney disease.Effects of combined administration of rapamycin, tolvaptan, and AEZ-131 on the progression of polycystic disease in PCK rats.Loss of Fnip1 alters kidney developmental transcriptional program and synergizes with TSC1 loss to promote mTORC1 activation and renal cyst formation.
P2860
Q27001230-7C5B0F8C-37BA-4274-B9DE-A9BC2B782FC5Q33872509-49165B8A-D918-483D-A9F9-450BD96E01A8Q34307356-6252D361-CF36-4718-8FE7-446910529CAFQ35964504-944D82F7-237C-4451-8F68-7A4827F07AB9Q37442070-43E0E06A-5A0C-4C28-831C-8C414088A915Q37604709-36C4F79E-7CA7-480C-B0FE-3A6961C65BD6Q38099698-1A322E15-362E-4517-BC5D-3CE5933F5152Q38171193-0FDCFD28-0756-4C92-BD26-8DBC26B41D62Q38173179-01EB525D-FD84-495E-ABA6-1323B3BD5EDBQ38838454-FED348C3-41F1-4557-9ECC-6C329BEC5FC8Q38978449-CD9D37C8-1560-46DB-8D12-CC4B0F91E83EQ38978468-F6AFFC44-84CC-4A08-B693-3737C5C9B430Q53958174-9BA75529-5BE5-476E-BD93-6E04718155F4Q54367200-66AC40BF-2F9B-4902-BD56-1E982621FF00Q55500213-E339942A-5377-48A4-867D-B95D62DBF295
P2860
The Raf kinase inhibitor PLX5568 slows cyst proliferation in rat polycystic kidney disease but promotes renal and hepatic fibrosis.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
The Raf kinase inhibitor PLX55 ...... es renal and hepatic fibrosis.
@en
The Raf kinase inhibitor PLX55 ...... es renal and hepatic fibrosis.
@nl
type
label
The Raf kinase inhibitor PLX55 ...... es renal and hepatic fibrosis.
@en
The Raf kinase inhibitor PLX55 ...... es renal and hepatic fibrosis.
@nl
prefLabel
The Raf kinase inhibitor PLX55 ...... es renal and hepatic fibrosis.
@en
The Raf kinase inhibitor PLX55 ...... es renal and hepatic fibrosis.
@nl
P2093
P2860
P356
P1476
The Raf kinase inhibitor PLX55 ...... tes renal and hepatic fibrosis
@en
P2093
Bernd Klanke
Bettina Kraenzlin
Bjoern Buchholz
Daisuke Yoshihara
Darren P Wallace
Gideon Bollag
Gunnar Schley
James Tsai
Kai-Uwe Eckardt
Norbert Gretz
P2860
P304
P356
10.1093/NDT/GFR432
P407
P577
2011-07-29T00:00:00Z